The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Prognostic value of MRD in elderly patients with secondary AML
Paola Minetto, MD, IRCCS Ospedale Policlinico San Martino, Genova, Italy, discusses the prognostic impact of measurable residual disease (MRD) assessment in elderly patients with secondary acute myeloid leukemia (AML) who receive induction therapy with either a fludarabine-containing regimen or CPX-351. Data from 136 elderly patients with secondary AML was analyzed. Dr Minetto reports that MRD demonstrated a significant prognostic value in terms of overall survival in all treatment groups and could help to identify elderly AML patients with a suboptimal response to treatment. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
